Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692467 | 1.00 | SLC18A3 (0.37) | SLC18A3LIPA | |
| SCHEMBL19382729 | 1.00 | SLC18A3 (0.37) | SLC18A3LIPA | |
| SCHEMBL19373753 | 1.00 | SLC18A3 (0.37) | SLC18A3LIPA | |
| SCHEMBL19039734 | 1.00 | SLC18A3 (0.37) | SLC18A3LIPA | |
| SCHEMBL13154332 | 1.00 | SLC18A3 (0.37) | SLC18A3LIPA | |
| SCHEMBL19822258 | 1.00 | SLC18A3 (0.37) | SLC18A3LIPA | |
| SCHEMBL26022179 | 0.81 | — | — | |
| SCHEMBL26022062 | 0.81 | — | — | |
| SCHEMBL14263470 | 0.78 | SLC18A3 (0.40) | SLC18A3LIPA | |
| SCHEMBL11133799 | 0.78 | SLC18A3 (0.40) | SLC18A3LIPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | SLC18A3 1759/4885LIPA 1436/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | SLC18A3 1759/4885LIPA 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.